🏛️ Verified NIH Record • Updated 2026-03-03
HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers (NCT06487403)
🟢 Recruiting Observational / Diagnostic 📋 Clinical Research Protocol Sponsor: University Health Network, Toronto
🩺 Plain-English Summary (8th-Grade Level)
This is a single centre prospective exploratory study of effects of radiation therapy on biomarker development in patients with newly diagnosed (head and neck squamous cell carcinoma) HNSCC receiving curative therapy. This research is part 2 of the HN-BIO study.
Who can join: Review the eligibility criteria below.
Location: Princess Margaret Cancer Centre — Toronto, Ontario
Age range: 18 Years
🧪 Interventions in This Study
- Standard of care external beam radiotherapy (single integrated boost) (RADIATION)
- Standard of care external beam radiotherapy (two-phase treatment) (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Princess Margaret Cancer Centre — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (416) 946-2132
Email: andrew.mcpartlin@rmp.uhn.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Squamous Cell Carcinoma of Head and Neck
- Pembrolizumab Plus Olaparib in LA-HNSCC — Indianapolis, Indiana
- TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC — Tampa, Florida
- HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer — Dallas, Texas
- MicroRNA Markers in Head and Neck Cancers — Aurora, Colorado
- A Clinical Trial Evaluating TG4050 in Head and Neck Cancer — Jacksonville, Florida
- A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer — La Jolla, California
Explore by condition: All Squamous Cell Carcinoma of Head and Neck clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.